As the Democratic Republic of the Congo grapples with the most rapidly expanding Ebola outbreak on record, GeoVax Labs, Inc. (Nasdaq: GOVX) has signaled its readiness to contribute its vaccine expertise and candidates to the global response. The outbreak, caused by the Bundibugyo virus (BDBV), has already resulted in more than 4,300 cases and 2,000 deaths, according to the World Health Organization (WHO), and is on a trajectory that could surpass the toll of the 2014-2016 West Africa epidemic. Currently, no approved vaccine specifically targets Bundibugyo virus.
GeoVax, a biotechnology company focused on infectious diseases and cancers, has extensive experience developing vaccines against high-consequence hemorrhagic fever viruses using its Modified Vaccinia Ankara (MVA) platform. The company’s portfolio includes candidates targeting Zaire ebolavirus, Sudan ebolavirus, and Marburg virus, all of which have demonstrated encouraging protective efficacy in non-human primate lethal-challenge studies.
David Dodd, Chairman and CEO of GeoVax, emphasized the importance of preparedness: “The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs.” He added that the company is prepared to engage with WHO, Africa CDC, and other public health authorities to determine how its candidates, technology, or scientific expertise could contribute.
GeoVax’s lead infectious disease priority remains GEO-MVA, its MVA-based vaccine candidate for mpox and smallpox. The company is preparing to initiate a pivotal clinical program using an immunobridging pathway, with portions expected to be conducted in African regions affected by infectious disease challenges, including areas impacted by the current Ebola outbreak. As part of these preparations, GeoVax has been engaging with healthcare and research organizations in the region, some of which are directly involved in responding to the Ebola outbreak. These relationships provide a natural opportunity to explore collaboration.
“Our relationships in the region are being developed first and foremost to advance GEO-MVA, but many of the organizations with whom we are engaging are simultaneously confronting this Ebola outbreak,” Dodd noted. “Given our experience, we believe it is appropriate to ask how we might help. Any such effort would be pursued collaboratively while maintaining our operational and capital focus on GEO-MVA.”
Beyond GEO-MVA, GeoVax retains a portfolio of MVA-based hemorrhagic fever vaccine candidates with protective efficacy in animal models. The company is open to discussions about collaborations, licensing arrangements, and public-private partnerships that could provide resources for further development without diverting primary resources from GEO-MVA. This broader portfolio offers strategic optionality as emerging infectious disease threats continue to arise.
The company’s dual focus on advancing GEO-MVA and leveraging its MVA platform for other threats reflects a strategy to build a scalable and independent source of MVA vaccine supply. GeoVax is also pursuing innovations in manufacturing, including a continuous cell-line process designed to improve scalability and cost-efficiency, and exploring single-dose regimens and microarray patch delivery technology.
With the Ebola outbreak showing no signs of abating, GeoVax’s offer to contribute its expertise and candidates could provide valuable support to global health efforts. The company’s willingness to collaborate, while maintaining its primary commitment to GEO-MVA, positions it as a potential partner in addressing this urgent public health challenge.
